AC
ORGO icon

Apogem Capital’s Organogenesis Holdings ORGO Stock Holding History

Apogem Capital’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-124,263
Closed -$936K – 201
2020
Q4 		$936K Buy
+124,263
New +$590K 0.62% 50

Other funds holding ORGO

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Apogem Capital's ORGO Position: Q1 2021 in Review

Apogem Capital sold out of Organogenesis Holdings (ORGO) in Q1 2021, closing a stake of 124,263 shares — an estimated $936K sold.

Apogem Capital first reported a position in ORGO in Q4 2020 and held it in 1 quarter. The position peaked at $936K in Q4 2020. 101 funds tracked by Wall St. Rank hold ORGO as of Q1 2021.

  • Apogem Capital reported no remaining Organogenesis Holdings position as of Q1 2021 after selling out during the quarter.
  • Apogem Capital sold 124,263 Organogenesis Holdings shares in Q1 2021, an estimated $936K.
  • Apogem Capital first reported a position in Organogenesis Holdings in Q4 2020 and held it in 1 quarter.
  • Apogem Capital's Organogenesis Holdings position peaked at $936K in Q4 2020.
  • 101 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2021.

Based on Apogem Capital's 13F filing for Q1 2021, filed 14 May 2021.